Helioxanthin derivative 5-4-2
CAS No. 203935-39-1
Helioxanthin derivative 5-4-2( —— )
Catalog No. M32957 CAS No. 203935-39-1
Helioxanthin derivative 5-4-2 (Helioxanthin 5-4-2) is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 566 | In Stock |
|
| 10MG | 805 | In Stock |
|
| 25MG | 1188 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHelioxanthin derivative 5-4-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionHelioxanthin derivative 5-4-2 (Helioxanthin 5-4-2) is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.
-
DescriptionHelioxanthin derivative 5-4-2 is an analogue ofhelioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.IC50 value: 0.08 uM (EC50) Target: Anti-HBV Helioxanthin derivative 5-4-2 had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 microM, respectively. The lamivudine-resistant HBV, L526M/M550V double mutant strain, was also sensitive to helioxanthin and 5-4-2. This class of compounds not only inhibited HBV DNA, but also decreased HBV mRNA and HBV protein expression. The EC50 of HBV DNA inhibition was consistent with the EC50 of HBV 3.5 Kb transcript inhibition, which was 1 and 0.09 microM for helioxanthin and 5-4-2 respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number203935-39-1
-
Formula Weight347.32
-
Molecular FormulaC20H13NO5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (143.96 mM; Ultrasonic )
-
SMILESO=C1NCc2c1cc1ccc3OCOc3c1c2-c1ccc2OCOc2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yeo H, et al. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem. 2005 Jan 27;48(2):534-46.?
molnova catalog
related products
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
-
DVR-01
DVR-01 is an HBV capsid inhibitor and can be used in studies about the treatment of Hepatitis B virus (HBV) infection and related conditions.
-
HBV Capsid inhibitor...
HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor.
Cart
sales@molnova.com